Twist Bioscience (NASDAQ:TWST) Now Covered by Analysts at UBS Group

Equities researchers at UBS Group initiated coverage on shares of Twist Bioscience (NASDAQ:TWST) in a research note issued on Wednesday, MarketBeat reports. The firm set a “neutral” rating and a $144.00 price target on the stock. UBS Group’s price target would suggest a potential upside of 12.45% from the stock’s current price.

A number of other brokerages have also weighed in on TWST. Guggenheim reiterated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 24th. Evercore downgraded shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price objective for the company. in a report on Monday, July 6th. Leerink Partners set a $110.00 target price on Twist Bioscience in a research report on Thursday, July 16th. Barclays lifted their price target on Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Wednesday, June 24th. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $103.80.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $128.06 on Wednesday. The company has a market capitalization of $8.03 billion, a P/E ratio of -57.68 and a beta of 2.22. The business has a fifty day simple moving average of $111.93 and a two-hundred day simple moving average of $77.92. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. Twist Bioscience has a 1 year low of $23.30 and a 1 year high of $155.44.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm had revenue of $118.38 million for the quarter, compared to the consensus estimate of $114.55 million. During the same quarter in the previous year, the company posted $0.33 EPS. The firm’s revenue was up 23.2% compared to the same quarter last year. On average, analysts expect that Twist Bioscience will post -2.12 earnings per share for the current year.

Insiders Place Their Bets

In other Twist Bioscience news, CEO Emily M. Leproust sold 113,318 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $125.16, for a total value of $14,182,880.88. Following the transaction, the chief executive officer directly owned 818,938 shares in the company, valued at $102,498,280.08. This represents a 12.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Adam Laponis sold 2,399 shares of the firm’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $94.33, for a total value of $226,297.67. Following the completion of the sale, the chief financial officer directly owned 110,276 shares in the company, valued at approximately $10,402,335.08. The trade was a 2.13% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 192,697 shares of company stock valued at $23,998,505 in the last ninety days. Corporate insiders own 3.08% of the company’s stock.

Institutional Trading of Twist Bioscience

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Allworth Financial LP bought a new position in Twist Bioscience in the second quarter valued at $62,000. Trifecta Capital Advisors LLC bought a new position in shares of Twist Bioscience during the 2nd quarter valued at about $63,000. Western Wealth Management LLC bought a new position in shares of Twist Bioscience during the 1st quarter valued at about $31,000. Strs Ohio purchased a new position in shares of Twist Bioscience during the 1st quarter valued at about $33,000. Finally, GAMMA Investing LLC raised its holdings in shares of Twist Bioscience by 24.4% during the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock valued at $97,000 after buying an additional 185 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.